Life Sciences and healthcare

Life sciences companies face an increasingly complex and competitive landscape. To succeed in this environment, industry leaders and start-ups, as well as their investors and capital providers, need a strong partner to navigate the unpredictable market. We can help.

Latest Insights, News, and Events

Latest Insights, News, and Events

Client Successes

Successfully defended Eli Lilly against patent infringement allegations by Sanofi involving medical device and formulation patents relating to Sanofi’s largest selling insulin

Serve as lead counsel to a global pharmaceutical company across four continents in high-profile government investigations and internal reviews

Advised Merck & Co. on major cross-border M&A transactions including its strategic agreement with Quartet Medicine, acquisition of Afferent Pharmaceuticals, and acquisition of therapeutics pioneer Rigontec

Represented Deerfield Management in the launch of a first-of-its-kind research partnership with the Broad Institute of MIT and Harvard, aimed at solving complex, early-stage therapeutic challenges related to serious unmet medical needs

Represented the lead arrangers in a US$900M bank financing for Bain Capital Private Equity's and J.H. Whitney Capital Partners' acquisition of Epic Health Services and PSA Healthcare

Tackling Industry Challenges with Core Competencies

We bring a global, interdisciplinary approach to support our life sciences and healthcare clients’ multifaceted needs – from providing strategic counsel with respect to critical intellectual property, to navigating compliance, investigations, and enforcement issues, to structuring transactions and financing arrangements, to developing first-of-its-kind innovative strategic partnerships and licensing arrangements, to advising on unique data governance issues, IoT development and roll-out, and proactive privacy/cybersecurity assessments.

We partner with clients to understand and advise on their business and legal objectives, delivering tailored solutions, creative strategies, innovative value-add offerings, and seamless service across practices and regions. Our lawyers handle complex transactional, regulatory, and litigation matters, providing guidance and insight into the industry as a whole. The diversity of our cumulative experience allows us to be lean and targeted in our support.


  • Paul Hastings has partnered with more than half of the top 50 life sciences companies by market capitalization.
  • Our lawyers represent the largest life sciences companies in complex domestic and international matters. We have secured a long string of litigation victories on behalf of our clients, including success in numerous high-stakes, bet-the-company patent litigations and post-grant proceedings.
  • Nearly every lawyer in our premier Intellectual Property practice has a technical degree in life sciences, engineering, or chemistry. The group includes PhD-level scientific advisors who have substantial experience in pharmaceutical patent litigation.
  • We advise life sciences companies on all aspects of anti-corruption law: conducting global risk assessments; leading internal investigations and negotiating with the DOJ, SEC, and foreign prosecutors; designing and enhancing compliance programs; overseeing due diligence in transactions; and negotiating debarment and related sanctions with the US government, World Bank, and other development banks.
  • We have a highly experienced team able to draw on industry and career-long expertise to increase efficiency and effectiveness on engagements across a range of disciplines. Our firsthand in-house, government, and research institution experience enables us to truly understand the client’s journey and tailor resources to specific assessments as needed.


  • Recognized as Life Sciences Practice Group of the Year by Law360.
  • Named a Life Sciences Dealmaker of the Year by The American Lawyer and Finance Monthly.
  • Chambers USA highlights “The team is known as an international firm with a strong U.S. footprint and sector expertise in life sciences and frequently called upon for strategically significant cross-border transactions.”
  • Chair of our Life Sciences practice, Bruce Wexler was named Transatlantic Lawyer of the Year – IP by The American Lawyer.
  • Partner David Shine was named a Dealmaker of the Year by The American Lawyer for his work advising Merck on the US$14.2B sale of its consumer care business.
  • Recognized as Most Valuable Players – Life Sciences and IP by Law360.
  • Winner of Four Awards by LMG Life Sciences including General Patent Litigator of the Year (New York), Post Grant Proceedings Attorney of the Year, and Two Impact Hatch-Waxman Cases of the Year.
  • Ranked in consecutive editions of Global Investigations Review GIR 100, for handling sophisticated cross-border government-led and internal investigations.